Bourbon...if I may interject....I understand that we are/were all hoping for better NEWS/results by now, but there is progress if you look at it. The update Meeting with FDA for discussing is encouraging...it is not "Planned to meet" anymore. I guess things are moving along now....into actions. Also, the cash position of $153.3 million is encouraging...looks like we have ended up with more money than last quarter in spite of spending over $10 million this quarter.
After the initial study for the P2 PDD trial was finished and TLDR was announced, I'm sure the FDA and Anavex wanted to see the longterm (48-week) results of the PDD OLE before starting a P3 trial...which could be pivotal.
Why spend all the time and money recruiting patients for a P3 trial when the OLE data won't be finished until June, 2022?